Showing 461 - 480 results of 66,899 for search '(( 50 ((n decrease) OR (mean decrease)) ) OR ( 5 ((a decrease) OR (teer decrease)) ))', query time: 1.09s Refine Results
  1. 461
  2. 462
  3. 463
  4. 464
  5. 465
  6. 466
  7. 467
  8. 468
  9. 469
  10. 470
  11. 471
  12. 472

    FUD transiently decreased IOP in mice injected with Ad5-TGFβ2 viral vector. by Jennifer A. Faralli (4907311)

    Published 2020
    “…(B) IOPs were monitored for 5 more days (until Day 22) in a subset of mice from A. …”
  13. 473

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
  14. 474

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  15. 475

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…Outpatient visit frequency also significantly declined from 11.5 ± 4.3 visits in the year before surgery to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g004" target="_blank">Fig 4</a>).…”
  16. 476

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  17. 477

    Image 1_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf by Francesca Bietto (21511316)

    Published 2025
    “…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
  18. 478

    Table 1_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.docx by Francesca Bietto (21511316)

    Published 2025
    “…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
  19. 479

    Image 4_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf by Francesca Bietto (21511316)

    Published 2025
    “…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
  20. 480

    Image 2_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf by Francesca Bietto (21511316)

    Published 2025
    “…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”